Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T13209
|
|||||
Target Name |
Activin receptor type II (ACVR2)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | Bimagrumab | Drug Info | Phase 2 | Type 2 diabetes | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Bimagrumab | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919. | |||||
REF 2 | ClinicalTrials.gov (NCT03005288) Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.